Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 6/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.36 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469349 | 0.90 | STAT3 (0.52) | STAT3PTPN11PTPROTP53MAPT | |
| SCHEMBL2469661 | 0.87 | STAT3 (0.49) | STAT3PTPN11PTPROTP53MAPT | |
| SCHEMBL2469748 | 0.85 | STAT3 (0.46) | STAT3PTPN11PTPROTP53MAPT | |
| SCHEMBL2470827 | 0.85 | STAT3 (0.50) | STAT3PTPN11PTPROTP53MAPT | |
| SCHEMBL2467356 | 0.80 | STAT3 (0.56) | STAT3PPARAKLKB1EIF4E | |
| SCHEMBL2470419 | 0.79 | STAT3 (0.51) | STAT3PTPN11PTPROKAT8 | |
| SCHEMBL2467885 | 0.77 | STAT3 (0.52) | STAT3TP53MAPTPPARAKLKB1 | |
| SCHEMBL2470089 | 0.77 | STAT3 (0.67) | STAT3PTPN11PTPROKAT8 | |
| SCHEMBL14208388 | 0.76 | STAT3 (0.49) | STAT3PPARAKLKB1EIF4E | |
| SCHEMBL2468824 | 0.75 | STAT3 (0.46) | STAT3PPARAKLKB1EIF4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | claimed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | claimed |
| US-20060189583-A1 | Aryl dicarboxamides | MERCK SERONO SA (CH) | 2006-08-24 | — | — | US | claimed |
| EP-1656139-A1 | ARYL DICARBOXAMIDES | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-17 | — | — | EP | claimed |
| WO-2005011685-A1 | ARYL DICARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | claimed |
| EP-1656139-B1 | ARYL DICARBOXAMIDES | MERCK SERONO SA (CH) | 2011-10-05 | — | — | EP | disclosed |
| EP-1656139-B1 | ARYL DICARBOXAMIDES | MERCK SERONO SA (CH) | 2011-10-05 | — | — | EP | disclosed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | disclosed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| US-7365225-B2 | Aryl dicarboxamides | LABORATOIRES SERONO SA (CH) | 2008-04-29 | — | — | US | disclosed |
| EP-1904048-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007009959-A1 | GLEPP-1 INHIBITORS IN THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
| US-20060189583-A1 | Aryl dicarboxamides | MERCK SERONO SA (CH) | 2006-08-24 | — | — | US | disclosed |
| EP-1656139-A1 | ARYL DICARBOXAMIDES | Applied Research Systems ARS Holding N.V. (AN) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005011685-A1 | ARYL DICARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189583-A1 | Aryl dicarboxamides | GPR119, PTPRS, ECHS1 | STAT3 3402/4885PTPN11 80/4885PTPRO 44/4885 |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | STAT3 2129/4885PTPN11 458/4885PTPRO 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.